Results 101 to 110 of about 49,940 (198)

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs.
Ana Maria Copaescu, Valentina Gueli, Jitesh Chahuan, Waad Albalawi, Giovanna Sfriso, Mattia Giovannini, Leticia de las Vecillas, Aspasia Karavelia, Marina Labella, Ruben Fernandez‐Santamaria, Francesca Mori, Lene H. Garvey, Patrizia Bonadonna, Maria Jose Torres   +13 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Vesicle Nucleation Peptide Fusion Induced Extracellular Vesicles Are Distinct From Escherichia coli Outer Membrane Vesicles, and Provide an Enhanced Platform for Protein Production and Purification

Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
In this study, Streather et al. show that the Vesicle Nucleating Peptide (VNp) drives formation of recombinant extracellular vesicles in E. coli that are compositionally distinct from native outer membrane vesicles (OMVs). Whereas OMVs contain heterogeneous periplasmic components and low, variable levels of recombinant cargo, Using a range of ...
Bree R. Streather, Tara A. Eastwood, Karen Baker, Mingzhi Liang, Alexandra E. Bailie, Tijn T. van der Velden, Lars J. C. Jeuken, Stanley W. Botchway, Lin Wang, Daniel P. Mulvihill   +9 more
wiley   +1 more source

PD‐1hiCXCR5−CD4+T Peripheral Helper Cells Were Enriched and Potentially Predicted Clinical Response to Etanercept Therapy in Rheumatoid Arthritis

MedComm, Volume 7, Issue 8, August 2026.
This study investigated the role of PD‐1hiCXCR5−CD4+ T peripheral helper (Tph) cells in rheumatoid arthritis (RA). Tph cells were increased in the peripheral blood of RA patients and associated with disease activity. Baseline Tph cell levels were linked to the response to etanercept therapy.
Haojie Xu, Wanki Ho, Lulu Cao, Dongdong Fu, Yun Li, Feng Sun, Xi Xu, Zhanguo Li, Ru Li, Hua Ye, Huaqun Zhu   +10 more
wiley   +1 more source

Lymphatic Endothelial Cells in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Lymphatic endothelial cells (LECs) are dynamic regulators of tissue homeostasis and disease remodeling. In the healthy state, LECs coordinate interstitial fluid drainage, intestinal lipid transport, and immune trafficking and tolerance. Across disease settings, however, these same programs become maladaptively reprogrammed, contributing to barrier ...
Du Tang, Wang Lin, Hengyang Liu, Jixin Zhong, Shiliang Li, Xiaoquan Rao   +5 more
wiley   +1 more source

Association Between Chikungunya Infection and Rheumatoid Arthritis in Taiwan—A Cross‐Sectional Study

International Journal of Rheumatic Diseases, Volume 29, Issue 8, August 2026.
ABSTRACT Objectives Chikungunya virus (CHIKV) infection might cause chronic chikungunya arthritis resembling rheumatoid arthritis (RA). The purpose of this study is to investigate the potential role of this virus in the pathogenesis of RA in Taiwan, a non‐endemic area. Methods This cross‐sectional study enrolled 98 RA patients and 200 healthy controls.
Chang‐Yi Yen, Chang‐Chi Lin, Ping‐Chang Lin, Ching‐Yi Tsai, Li‐Teh Liu, Chen‐Hsuan Lin, Chun‐Hong Chen, Chia‐Chun Tseng, Hua‐Chen Chan, Cheng‐Chin Wu, Tsan‐Teng Ou, Jih‐Jin Tsai, Jeng‐Hsien Yen   +12 more
wiley   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

A Systematic Review of Literature: TNF-α Blockers and JAK Inhibitors for the Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme. [PDF]

Health Sci Rep
Salehi S, Torabi P, Abbaspour M, Hajizadeh N, Sadeghi S, Jafarzadeh A, Goodarzi A.   +6 more
europepmc   +1 more source